DK1042307T3 - Aminothiazolinhibitorer af cyclinafhængige kinaser - Google Patents

Aminothiazolinhibitorer af cyclinafhængige kinaser

Info

Publication number
DK1042307T3
DK1042307T3 DK98956431T DK98956431T DK1042307T3 DK 1042307 T3 DK1042307 T3 DK 1042307T3 DK 98956431 T DK98956431 T DK 98956431T DK 98956431 T DK98956431 T DK 98956431T DK 1042307 T3 DK1042307 T3 DK 1042307T3
Authority
DK
Denmark
Prior art keywords
aminothiazoline
cyclin
inhibitors
dependent kinases
kinases
Prior art date
Application number
DK98956431T
Other languages
Danish (da)
English (en)
Inventor
John T Hunt
S David Kimball
Michael A Poss
Raj N Misra
Zhen-Wei Cai
David B Rawlins
Kevin Webster
Wen-Ching Han
Kyoung S Kim
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of DK1042307T3 publication Critical patent/DK1042307T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
DK98956431T 1997-11-12 1998-11-02 Aminothiazolinhibitorer af cyclinafhængige kinaser DK1042307T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6519597P 1997-11-12 1997-11-12
PCT/US1998/023197 WO1999024416A1 (en) 1997-11-12 1998-11-02 Aminothiazole inhibitors of cyclin dependent kinases

Publications (1)

Publication Number Publication Date
DK1042307T3 true DK1042307T3 (da) 2008-01-28

Family

ID=22060972

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98956431T DK1042307T3 (da) 1997-11-12 1998-11-02 Aminothiazolinhibitorer af cyclinafhængige kinaser

Country Status (32)

Country Link
US (1) US6040321A (el)
EP (1) EP1042307B1 (el)
JP (1) JP4344084B2 (el)
KR (2) KR20030036862A (el)
CN (1) CN1160343C (el)
AR (1) AR017182A1 (el)
AT (1) ATE374771T1 (el)
AU (1) AU730607B2 (el)
BR (1) BR9814124A (el)
CA (1) CA2309551C (el)
CO (1) CO4990957A1 (el)
CY (1) CY1107509T1 (el)
CZ (1) CZ297907B6 (el)
DE (1) DE69838515T2 (el)
DK (1) DK1042307T3 (el)
EG (1) EG24028A (el)
ES (1) ES2296347T3 (el)
HU (1) HUP0004559A3 (el)
ID (1) ID23983A (el)
IL (1) IL135589A (el)
MY (1) MY120779A (el)
NO (1) NO316773B1 (el)
NZ (1) NZ503828A (el)
PE (1) PE131699A1 (el)
PL (1) PL204642B1 (el)
PT (1) PT1042307E (el)
RU (1) RU2211839C2 (el)
TR (1) TR200001344T2 (el)
TW (1) TW593292B (el)
UY (1) UY25239A1 (el)
WO (1) WO1999024416A1 (el)
ZA (1) ZA9810332B (el)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262096B1 (en) 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6414156B2 (en) * 1998-10-21 2002-07-02 Bristol-Myers Squibb Company Process for preparing azacycloalkanoylaminothiazoles
US6214852B1 (en) * 1998-10-21 2001-04-10 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US6337338B1 (en) * 1998-12-15 2002-01-08 Telik, Inc. Heteroaryl-aryl ureas as IGF-1 receptor antagonists
US20040171632A1 (en) * 1998-12-22 2004-09-02 Gowan Richard Carleton Combination chemotherapy
ES2253928T3 (es) * 1998-12-22 2006-06-01 Warner-Lambert Company Llc Quimioterapia de combinacion que comprende un inhibidor mitotico y un inhibidor mek.
CN1148349C (zh) * 1999-04-07 2004-05-05 参天制药株式会社 N-取代-N′-取代脲衍生物及其用作TNF-α生成抑制剂的用途
RU2260592C9 (ru) 1999-04-15 2017-04-07 Бристол-Маерс Сквибб Ко. Циклические ингибиторы протеинтирозинкиназ
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
UA71971C2 (en) * 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
WO2001007411A1 (fr) * 1999-07-26 2001-02-01 Banyu Pharmaceutical Co., Ltd. Derives de biaryluree
US6114365A (en) * 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
MY125768A (en) * 1999-12-15 2006-08-30 Bristol Myers Squibb Co N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US6515004B1 (en) 1999-12-15 2003-02-04 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US6392053B2 (en) 1999-12-15 2002-05-21 Bristol-Myers Squibb Company Process for preparing arylacetylaminothiazoles
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
WO2001056567A1 (en) * 2000-02-04 2001-08-09 Novo Nordisk A/S 2,4-diaminothiazole derivatives and their use as glycogen synthase kinase-3 (gsk-3) inhibitors
IT1317826B1 (it) * 2000-02-11 2003-07-15 Dompe Spa Ammidi, utili nell'inibizione della chemiotassi dei neutrofiliindotta da il-8.
AU2001249865A1 (en) 2000-04-18 2001-10-30 Agouron Pharmaceuticals, Inc. Pyrazoles for inhibiting protein kinase
US6534531B2 (en) * 2000-04-27 2003-03-18 Bristol-Myers Squibb Company Methods for preventing and treating alopecia induced by chemotherapy or radiotherapy
WO2001095856A2 (en) * 2000-06-15 2001-12-20 Chaconne Nsi Co., Ltd. Urea derivative useful as an anti-cancer agent and process for preparing same
CA2417254A1 (en) * 2000-07-26 2002-02-07 Bristol Myers Squibb Company N-¢5-¢¢¢5-alkyl-2-oxazolyl!methyl!thio!-2-thiazolyl! carboxamide inhibitors of cyclin dependent kinases
WO2002012250A2 (en) 2000-08-09 2002-02-14 Agouron Pharmaceuticals, Inc. Pyrazole-thiazole compounds, pharmaceutical compositions containing them, and methods of their use for inhibiting cyclin-dependent kinases
US20020173507A1 (en) * 2000-08-15 2002-11-21 Vincent Santora Urea compounds and methods of uses
US6645990B2 (en) 2000-08-15 2003-11-11 Amgen Inc. Thiazolyl urea compounds and methods of uses
AU3113902A (en) * 2000-12-21 2002-07-01 Bristol Myers Squibb Co Thiazolyl inhibitors of tec family tyrosine kinases
US6756374B2 (en) 2001-01-22 2004-06-29 Hoffmann-La Roche Inc. Diaminothiazoles having antiproliferative activity
BRPI0206509B8 (pt) 2001-01-25 2021-05-25 R Pharm Us Operating Llc processo para formular, para administração parenteral, um análogo de epotilona, preparação farmacêutica, processo para formar uma composição farmacêutica para administração parental, composição farmacêutica e uso de um análogo de epotilona na preparação de uma composição farmacêutica para o tratamento de câncer
BR0208142A (pt) * 2001-03-19 2004-03-02 Novartis Ag Combinações compreendendo um agente antidiarréico e epotilona ou derivado de epotilona
ATE315555T1 (de) 2001-05-11 2006-02-15 Pfizer Prod Inc Thiazolderivate und ihre verwendung als cdk- inhibitoren
US20030176443A1 (en) * 2001-05-16 2003-09-18 Matthias Stein-Gerlach Pyridylpyrimidine derivatives as effective compounds against prion diseases
CA2447475A1 (en) 2001-05-25 2002-12-05 Chu-Biao Xue Hydantion derivatives as inhibitors of matrix metalloproteinases
HN2002000156A (es) 2001-07-06 2003-11-27 Inc Agouron Pharmaceuticals Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización.
KR100908794B1 (ko) * 2001-07-19 2009-07-22 파마시아 이탈리아 에스.피.에이. 페닐아세트아미도-티아졸 유도체, 이의 제조방법 및 이를 포함하는 항종양제로서의 약제학적 조성물
HUP0402341A3 (en) * 2001-08-31 2005-11-28 Bristol Myers Squibb Company P Compositions containing thiazol-2-ylamines for the treatment of cancer
US7405234B2 (en) * 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
TW200401638A (en) * 2002-06-20 2004-02-01 Bristol Myers Squibb Co Heterocyclic inhibitors of kinases
CA2744893A1 (en) 2002-06-27 2004-01-08 Novo Nordisk A/S Aryl carbonyl derivatives as glucokinase activators
CA2497539A1 (en) * 2002-09-04 2004-03-18 Schering Corporation Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7161003B1 (en) * 2002-09-04 2007-01-09 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
WO2004026229A2 (en) * 2002-09-04 2004-04-01 Schering Corporation Pyrazolo[1,5-a]pyrimidines compounds as cyclin dependent kinase inhibitors
US7196078B2 (en) * 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
EP1534709B1 (en) * 2002-09-04 2007-06-13 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
AR041136A1 (es) * 2002-09-04 2005-05-04 Pharmacopeia Drug Discovery Pirazolopirimidinas como inhibidores de cinasas dependientes de clclinas
US7205308B2 (en) * 2002-09-04 2007-04-17 Schering Corporation Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
PL375149A1 (en) 2002-10-03 2005-11-28 F.Hoffmann-La Roche Ag Indole-3-carboxamides as glucokinase (gk) activators
KR20050074959A (ko) * 2002-10-03 2005-07-19 노파르티스 아게 제ｉｉ형 당뇨병 치료에 유용한 글루코키나아제 활성인자로서의 치환된 (티아졸-２-일)-아미드 또는 술폰아미드
BR0315580A (pt) * 2002-10-24 2005-08-30 Merck Patent Gmbh Derivados de metileno uréia
AU2003302084A1 (en) * 2002-11-15 2004-06-15 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
EP1656542A4 (en) * 2003-07-29 2008-09-03 Bristol Myers Squibb Co BIOMARKER OF MODULATION CYCLIN-DEPENDENT KINASE
US6949895B2 (en) * 2003-09-03 2005-09-27 Axcelis Technologies, Inc. Unipolar electrostatic quadrupole lens and switching methods for charged beam transport
US7256208B2 (en) * 2003-11-13 2007-08-14 Bristol-Myers Squibb Company Monocyclic N-Aryl hydantoin modulators of androgen receptor function
JP2007513967A (ja) * 2003-12-11 2007-05-31 セラヴァンス， インコーポレーテッド 変異レセプターチロシンキナーゼが駆動する細胞増殖性疾患の処置において使用するための組成物
PL1723128T3 (pl) 2004-01-06 2013-04-30 Novo Nordisk As Pochodne heteroarylowe mocznika oraz ich zastosowanie jako aktywatory glukokinazy
WO2005072731A1 (en) * 2004-01-29 2005-08-11 X-Ceptor Therapeutics, Inc. 3-phenyl-n- ((1, 3, 4) thiadiazol-2-yl) -acrylamide derivatives and related compounds as modulators of estrogen-related receptors for the treatment of e.g. cancer, rheumatoid arthritis or neurological disorders
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
AU2005210474B2 (en) * 2004-01-30 2011-07-07 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding cassette transporters
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US20050182105A1 (en) * 2004-02-04 2005-08-18 Nirschl Alexandra A. Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function
EP1568368A1 (en) * 2004-02-26 2005-08-31 Schering Aktiengesellschaft Pharmaceutical combination comprising a CDK inhibitor and a VEGF receptor inhibitor
US7378426B2 (en) 2004-03-01 2008-05-27 Bristol-Myers Squibb Company Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7388027B2 (en) * 2004-03-04 2008-06-17 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7696241B2 (en) * 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7211576B2 (en) 2004-04-20 2007-05-01 Hoffmann-La Roche Inc. Diaminothiazoles
CN101083978A (zh) 2004-11-18 2007-12-05 布里斯托尔-迈尔斯斯奎布公司 含有伊沙贝比隆的肠衣珠粒及其制备
US20100105745A1 (en) * 2005-01-04 2010-04-29 Toshinari Minamoto Suppression of cancer and method for evaluating anticancer agent based on the effect of inhibiting gsk3 beta
EP1845094A4 (en) * 2005-01-04 2009-12-16 Univ Kanazawa Nat Univ Corp METHOD OF TUMOR SUPPRESSION AND EVALUATION OF ANTICANCER AGENT BASED ON THE INHIBITORY EFFECT OF GSK3 BETA
ES2382815T3 (es) 2005-07-08 2012-06-13 Novo Nordisk A/S Dicicloalquilcarbamoil ureas como activadores de glucoquinasa
CA2615938C (en) * 2005-07-14 2014-04-29 Novo-Nordisk A/S Urea glucokinase activators
JP2009515984A (ja) * 2005-11-15 2009-04-16 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼ阻害剤として有用なアザインダゾール
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7888504B2 (en) * 2006-07-06 2011-02-15 Bristol-Myers Squibb Company Glucokinase activators and methods of using same
WO2008049856A2 (en) * 2006-10-25 2008-05-02 Ingenium Pharmaceuticals Gmbh Methods of treating pain using cdk inhibitors
CN101600728A (zh) 2006-12-04 2009-12-09 伊利诺斯大学理事会 使用铜氧还蛋白和富含CpG的DNA治疗癌症的组合物和方法
CA2784807C (en) 2009-12-29 2021-12-14 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
SG185414A1 (en) 2010-05-12 2012-12-28 Univ Vanderbilt Heterocyclic sulfone mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
ES2685171T3 (es) 2010-06-14 2018-10-05 The Scripps Research Institute Reprogramación de células a un nuevo destino
AU2011323682B2 (en) * 2010-11-01 2016-06-23 Romark Laboratories L.C. Alkylsulfinyl-substituted thiazolide compounds
AU2012207142B2 (en) 2011-01-20 2017-04-27 Board Of Regents, The University Of Texas System MRI markers, delivery and extraction systems, and methods of manufacture and use thereof
CN102863474A (zh) 2011-07-09 2013-01-09 陈小平 一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
CN102993239A (zh) 2011-09-19 2013-03-27 陈小平 离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
US8940742B2 (en) * 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP2924044B1 (en) 2012-11-17 2018-10-31 Beijing Shuobai Pharmaceutical Co., LTD Platinum compound of malonic acid derivative having leaving group containing amino or alkylamino
JP6579623B2 (ja) * 2013-03-15 2019-09-25 ザ・スクリップス・リサーチ・インスティテュート 軟骨形成を誘導するための化合物及び方法
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
DK3052485T3 (da) 2013-10-04 2021-10-11 Infinity Pharmaceuticals Inc Heterocykliske forbindelser og anvendelser deraf
DK3119397T3 (da) 2014-03-19 2022-03-28 Infinity Pharmaceuticals Inc Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser
GB201409471D0 (en) * 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
WO2016160617A2 (en) 2015-03-27 2016-10-06 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
US11142507B2 (en) 2015-09-09 2021-10-12 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
JP6980649B2 (ja) 2015-09-14 2021-12-15 インフィニティー ファーマシューティカルズ， インコーポレイテッド イソキノリノン誘導体の固体形態、それを製造する方法、それを含む組成物、及びそれを使用する方法
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
EP3440063B1 (en) * 2016-04-06 2020-08-05 Innovative Molecules GmbH Aminothiazole derivatives useful as antiviral agents
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA3040155C (en) 2016-10-11 2024-01-16 Euro-Celtique S.A. Compound for use in the treatment of hodgkin lymphoma
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
GB201709405D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
HRP20230158T1 (hr) 2017-10-05 2023-03-31 Innovative Molecules Gmbh Enantiomeri supstituiranih tiazola kao antivirusni spojevi
EP3806852A1 (en) 2018-06-12 2021-04-21 vTv Therapeutics LLC Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
EP4229037A2 (en) * 2020-10-16 2023-08-23 CeMM - Forschungszentrum für Molekulare Medizin GmbH Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1088049A (en) * 1975-06-03 1980-10-21 Takashi Masugi 3-substituted-7-substituted alkanamido-3-cephem-4- carboxylic acid compounds and processes for preparation thereof
NO831160L (no) * 1982-04-08 1983-10-10 Erba Farmitalia Fremstilling av substituerte penem-derivater
JPS6339868A (ja) * 1986-08-04 1988-02-20 Otsuka Pharmaceut Factory Inc ジ低級アルキルフエノ−ル誘導体
DE4119756A1 (de) * 1991-06-15 1992-12-17 Basf Ag Aminoalkylsubstituierte 5-mercaptothiazole, ihre herstellung und verwendung
JPH0859669A (ja) * 1994-06-13 1996-03-05 Takeda Chem Ind Ltd セフェム化合物、その製造法及び剤

Also Published As

Publication number Publication date
EP1042307A4 (en) 2003-01-29
RU2211839C2 (ru) 2003-09-10
CN1278806A (zh) 2001-01-03
DE69838515T2 (de) 2008-07-03
EP1042307B1 (en) 2007-10-03
IL135589A0 (en) 2001-05-20
ID23983A (id) 2000-06-14
BR9814124A (pt) 2000-10-03
UY25239A1 (es) 2000-12-29
CZ297907B6 (cs) 2007-04-25
PE131699A1 (es) 2000-03-08
KR100454426B1 (ko) 2004-10-26
CA2309551C (en) 2006-03-28
IL135589A (en) 2004-06-20
HUP0004559A1 (hu) 2002-04-29
NZ503828A (en) 2003-03-28
PL340540A1 (en) 2001-02-12
NO316773B1 (no) 2004-05-03
PL204642B1 (pl) 2010-01-29
CZ20001744A3 (en) 2001-05-16
CO4990957A1 (es) 2000-12-26
TR200001344T2 (tr) 2000-09-21
KR20010031896A (ko) 2001-04-16
PT1042307E (pt) 2007-11-15
JP4344084B2 (ja) 2009-10-14
NO20002153D0 (no) 2000-04-27
KR20030036862A (ko) 2003-05-09
CY1107509T1 (el) 2013-03-13
AR017182A1 (es) 2001-08-22
AU1295599A (en) 1999-05-31
AU730607B2 (en) 2001-03-08
CN1160343C (zh) 2004-08-04
JP2001522842A (ja) 2001-11-20
DE69838515D1 (de) 2007-11-15
EG24028A (en) 2008-03-26
MY120779A (en) 2005-11-30
US6040321A (en) 2000-03-21
WO1999024416A1 (en) 1999-05-20
EP1042307A1 (en) 2000-10-11
ZA9810332B (en) 2000-05-11
NO20002153L (no) 2000-05-11
ATE374771T1 (de) 2007-10-15
TW593292B (en) 2004-06-21
ES2296347T3 (es) 2008-04-16
CA2309551A1 (en) 1999-05-20
HUP0004559A3 (en) 2002-05-28

Similar Documents

Publication Publication Date Title
DK1042307T3 (da) Aminothiazolinhibitorer af cyclinafhængige kinaser
DK1183033T3 (da) Pyrrolotriazininhibitorer af kinaser
EE200000289A (et) Asendatud 4-amino-tiasool-2-üüli ühendid kui tsükliinisõltuvusega kinaaside inhibiitorid
NO20002121D0 (no) Benzotiazol-protein-tyrosin-kinaseinhibitorer
DK1077943T3 (da) Heterocykliske inhibitorer af p38
DK1064298T3 (da) Inhibitorer af caspaser
ID22982A (id) PIRAZOL-PIRAZOL TERSUBSTITUSI SEBAGAI INHIBITOR KINASE p38
DK0986309T3 (da) Anvendelse af olielegemer
DZ3223A1 (fr) Inhibiteurs de tyrosine kinases
NO20013751D0 (no) Purininhibitorer av cyklinavhengig kinase 2 og IKB-<alfa>
DK0975778T3 (da) Anvendelse af glyphostat-resistende majslinier
DE69905683D1 (de) Pyrimidineihibitoren der HIV-Replikation
DE69716615D1 (de) Heterozyklische metalloproteaseinhibitoren
DK0984957T3 (da) Hidtil ukendt form af S-omeprazol
NO20004217D0 (no) Inhibitorer av fosfolipase A2
NO20022864L (no) Aminotiazol inhibitorer av syklin uavhengig kinase
DK0958287T3 (da) Sulfamidmetalloprotease-inhibitorer
DK1027332T3 (da) Hidtil ukendte lactametalloproteaseinhibitorer
PT927183E (pt) Inibidores espirociclicos de metaloproteases
DK1307263T3 (da) Hidtil ukendt anvendelse af lipaseinhibitorer
DK1047450T3 (da) Kombinationer af ACE-inhibitorer og MMP-inhibitorer
DK0788496T3 (da) Inhibitorer for syntese af apolipoprotein-B
ID22650A (id) Penggunaan penghambat-penghambat lipase usus lambung
IS5772A (is) Þalazín (phthalazine) afleiður af fosfódíesterasa4 lötum
DE69831950D1 (de) Inhibitoren des hitzeschock-faktors